Here, we unravel that chemotherapy-induced acetylation of ACLY by NAT10 drives the chemoresistance in HCC through controlling nuclear acetyl-CoA production to activate the transcription of CYP2C9 and PIK3R1 genes (Fig. 8J). This evidence concerns the gene NAT10 and hepatocellular carcinoma.